The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 363-368

  Watanabe, Yoh ^a   Nakai, Hidekatsu ^a   Hoshiai, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP3A; Doxorubicin; Etoposide; Granisetron; Irinotecan

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CORTICOSTEROID; CYTOCHROME P450 3A; DOXORUBICIN; ETOPOSIDE; GRANISETRON; IRINOTECAN; KETOCONAZOLE; LIVER ENZYME; OXIDOREDUCTASE; QUERCETIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER; LIVER MICROSOME; NAUSEA; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIEMETICS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; ETOPOSIDE; GRANISETRON; HUMANS; MICROSOMES, LIVER;

EID: 16844362017     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X36404     Document Type: Article

References (33)

1. Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 2003;90:S1-7
2. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22
3. Greco FA. Oral etoposide in lymphoma. Drugs 1999;58(Suppl 3):35-41
4. Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review. Cancer Treat Rev 2002;28:237-53
5. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003;30:9-25
6. Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol 2003;26:358-62
7. Benson 3rd AB, Goldberg RM. Optimal use of the combination of irinotecan and 5-fluorouracil. Semin Oncol 2003;30(Suppl 6):68-77
8. Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003;21:291-7
9. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. An ASCO special article. J Clin Oncol 1999;17:2971-94
10. Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990;188:301-12
11. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-8
12. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002;8:405-14
13. Yancik R, Ries LAG. Aging and cancer in America. Hematol Oncol Clin North Am 2000;14:17-23
14. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives in comorbidity and cancer in older patients: approaches to expanding the knowledge base. J Clin Oncol 2001;19:1147-54
15. Jörgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001;35:1004-9
16. Riechelmann RP, Smaletz Ó, Saad ED. Drug interactions in cancer patients. Proc Am Soc Clin Oncol 2004;23:761 [abstract 8146]
17. Lee HJ, Lee MG. Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res Commun Mol Pathol Pharmacol 1999;105:87-96
18. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998;286:1294-300
19. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-20
20. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmac 1994;38:557-66
21. Watanabe Y, Nakajima H, Nozaki K, Hoshiai H, Noda K. The effect of granisetron on in vitro metabolism of paclitaxel and docetaxel. Cancer J 2003;9:67-70
22. de Bruijn P, Verweij J, Loos WJ, et al. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999;266:216-21
23. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998;58:468-72
24. Kumakura H, Koyanagi J, Nisioka Y, et al. Phase I study of granisetron (second report) - pharmacokinetics of granisetron following single and repeat intravenous drip infusion in Japanese healthy volunteers. J Clin Ther Med 1990;6:25-34
25. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992;6:752-8
26. Karas S. The potential for drug interactions. Ann Emerg Med 1981;10:627-30
27. MASCC. Antiemetic guidelines from the consensus conference on antiemetic therapy. Perugia International Cancer Conference VII, 29-31 March 2004, Perugia, Italy. Available at www.mascc.org [accessed January 2005]
28. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19
29. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine. J Psychopharmacol 1999;13:313-7
30. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999;24:1-4
31. De Witte JL, Schoenmaekers B, Sessler DI, Deloof T. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 2001;92:1319-21
32. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-11
33. Kim M-K, Cho J-Y, Lim H-S, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol 2003;59:111-16